drug · small molecule
elacestrant hydrochloride
Marketedupdated 5mo agoby A. Menarini Industrie Farmaceutiche Riunite Srl🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for male breast carcinoma and breast neoplasm and 1 investigational indication.
targets
Estrogen receptor
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 27, 2028
~1.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (14)
- Jan 5, 2038compositionUS 10385008
- Jan 5, 2038compositionUS 10385008
- Jan 5, 2038method-of-use (U-3523)US 10745343
- Jan 5, 2038method-of-use (U-3523)US 10745343
- Feb 28, 2037method-of-use (U-3523)US 11819480
- Feb 28, 2037method-of-use (U-3523)US 11819480
- Oct 3, 2036method-of-use (U-3524)US 10420734
- Oct 3, 2036method-of-use (U-3524)US 10420734
- Oct 10, 2034method-of-use (U-3524)US 10071066
- Oct 10, 2034method-of-use (U-3524)US 10071066
- Oct 10, 2034method-of-use (U-3524)US 11779552
- Oct 10, 2034method-of-use (U-3524)US 11779552
- Aug 18, 2026compositionUS 7612114
- Aug 18, 2026compositionUS 7612114
FDA exclusivities (2)
- Jan 27, 2028NCENew Chemical Entity (5y)1.3y
- Jan 27, 2028NCENew Chemical Entity (5y)1.3y
News(3)
- FDA approves AstraZeneca’s Etcamah, opening ctDNA-guided treatment paradigm in breast cancerIn a rare divergence from its own expert panel, the FDA has granted accelerated approval to AstraZeneca’s camizestrant, turning a contentious regulatory review into a landmark win that opens a new…fiercebiotech · 25d ago
- Dr McCann on the FDA Approval of Vepdegestrant for ESR1-Mutated, ER+ Advanced Breast CancerKelly Elizabeth McCann, MD, PhD, notes the role of vepdegestrant in the ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treatment paradigm.onclive · 4mo ago
- Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drugA deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.biopharma_dive · 4mo ago
Data sources
last refreshed 33m ago
Found something off?
comments(0)
5-min edit window · permanent after that